| Literature DB >> 26919251 |
Esther Diana Rossi1, Tommaso Bizzarro1, Maurizio Martini1, Patrizia Straccia1, Celestino Pio Lombardi2, Alfredo Pontecorvi3, Luigi Maria Larocca1, Guido Fadda1.
Abstract
We assess the role of thyroid fine needle aspiration cytology(FNAC) in our series of elderly patients. The growing subset of people aged older than 70 years has shown an increased incidence of thyroid diseases which need to be studied in order to reduce the percentage of surgical treatments in patients with higher likelihood of co-morbidities and associated life risk. We compared Follicular/Indeterminate Neoplasms(FN) and suspicious of malignancy(SM) with pediatric and adult cohorts. We discussed the role of immunocytochemistry-ICC to refine diagnoses. Four hundred and eighty out of 3539FNACs(13.5%) in elderly patients, were surgical followed-up. They included: 35Inadequate, 188benign(BL), 164FN/AUS, 49SM and 44positive for malignancy (PM). All PM and 95.7%BL were histological confirmed. The malignant rate was 24.3% mostly diagnosed as papillary thyroid carcinomas. An ICC panel (HBME-1 and Galectin-3) was carried out on liquid based cytology (LBC) and performed on FN/AUS, SM and PM.We found concordant positive ICC in 69.3%malignancies and concordant negative ICC in 97.6%benign follicular adenomas. Among FNs, 42.9%malignant histologic cases had concordant positivity whilst 97.4%benign histology had negative panel.Thyroid FNAC shows high feasibility in elderly patients. ICC helps in reducing the number of useless thyroidectomies and providing a more adequate clinical and/or surgical selection in elderly patients.Entities:
Keywords: Gerotarget; elderly patients; immunocytochemistry; liquid based cytology; malignancies; thyroid lesions
Mesh:
Year: 2016 PMID: 26919251 PMCID: PMC4914252 DOI: 10.18632/oncotarget.7643
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinico-pathological features of the series including 480 elderly patients with surgical follow-up
| Clinical Features | No. of cases (%) |
|---|---|
| Sex, n | |
| Male | 129 (26.8%) |
| Female | 351 (73.2%) |
| Age range (median) | |
| 70-95 y.o. | 480 (79 y.o.) |
| Size, n | |
| < 2 cm | 336 (70%) |
| > 2 cm | 144 (30%) |
| Cytology, n | |
| TIR1 | 35 (7.3%) |
| TIR2 | 188 (39.2%) |
| TIR3 | 164 (34.2%) |
| TIR4 | 49 (10.2%) |
| TIR5 | 44 (9.1%) |
| Histology, n | |
| Goiter | 213 (44.5%) |
| Adenoma | 150 (31.3%) |
| PTC | 59 (12.3%) |
| FVPTC | 37 (7.7%) |
| FTC | 5 (1%) |
| MTC | 6 (1.2%) |
| HCC | 6 (1.2%) |
| ATC | 3 (0.6%) |
| Sarcoma | 1 (0.2%) |
| T- Stage, n | |
| TI-TII | 99 (84.6%) |
| TIII-TIV | 18 (15.4%) |
| N-Stage, n | |
| pNO | 106 (90.6%) |
| pN1 | 11 (9.4%) |
Legend: PTC:Papillary thyroid carcinoma; FVPTC: Follicular variant of PTC; FTC: Follicular carcinoma; MTC: Medullary thyroid carcinoma; HCC: Hurthle cell carcinoma; ATC: Anaplastic Thyroid carcinoma. N0: negative lymph nodes; Pn1: positive lymph nodes.
Cyto-histological correlation in the series
| CYTOLOGY (n) | HISTOLOGY (n) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goiter | FA | BENIGN CASES | PTC | FVPC | FTC | MTC | HCC | ATC | Sarcoma | MALIGNANT CASES | ROM | |
| TIR1 (35) | 22 | 9 | 31 | 2 | 2 | - | - | - | - | - | 4 | 11.4% |
| TIR2 (188) | 149 | 31 | 180 | 3 | 3 | 1 | 1 | - | - | - | 8 | 4.3% |
| TIR3 (164) | 39 | 94 | 133 | 9 | 14 | 3 | - | 5 | - | - | 31 | 18.9% |
| TIR4 (49) | 3 | 16 | 19 | 13 | 13 | 1 | 1 | 1 | - | 1 | 30 | 61.2% |
| TIR5 (44) | - | - | 0 | 32 | 5 | - | 4 | - | 3 | - | 44 | 100.0% |
| Tot. (480) | 213 | 150 | 363 | 59 | 37 | 5 | 6 | 6 | 3 | 1 | 117 | 24.4% |
FA: Follicular adenoma; PTC: Papillary thyroid carcinoma; FVPTC: Follicular variant of PTC; FTC: Follicular carcinoma; MTC: Medullary thyroid carcinoma; HCC: Hurthle cell carcinoma; ATC: Anaplastic Thyroid carcinoma. pN0: negative lymph nodes; pN1: positive lymph nodes; ROM: risk of malignancy.
Comparative analysis among the different cohorts of patients
| Cytological Categories | Distribution of cases into age groups, n (%) | ||
|---|---|---|---|
| 0-18 y.o. | 19-69 y.o. | 70-95 y.o. | |
| TIR1 | 22 (10%) | 3400 (13%) | 613 (17%) |
| TIR2 | 123 (56%) | 16382 (62%) | 2184 (62%) |
| TIR3 | 47 (21%) | 4861 (18,5%) | 577 (16%) |
| TIR4 | 17 (8%) | 913 (3,5%) | 84 (2,5%) |
| TIR5 | 11 (5%) | 829 (3%) | 81 (2,5%) |
| TOT | 220 | 26385 | 3539 |
The distribution of categories is accordingly to those reported in methods.
Figure 1Graphic representation of the distribution of the three cohorts of patients set up according to age
Cyto-histological correlation for the ICC panel (FN/AUS, SM and PM)
| ICC | Histological Diagnoses, n (%) | ||
|---|---|---|---|
| Benign | Malignant | Overall | |
| HBME1 - / Galectin3 - | 81 (97.6%) | 2 (2.4%) | 83 |
| HBME1 + / Galectin3 + | 32 (30.7%) | 72 (69.3%) | 104 |
| HBME1 + / Galectin3 - | 16 (44.4%) | 20 (55.6%) | 36 |
| HBME1 - / Galectin3 + | 23 (67.6%) | 32.4%) | 34 |
Legend: ICC: Immunocytochemistry.
p-value <0.005
Cyto-histological correlation for the ICC panel (FN/AUS)
| ICC | Histological Diagnoses, n (%) | ||
|---|---|---|---|
| Benign | Malignant | Overall | |
| HBME1 - / Galectin3 - | 75 (97.4%) | 2 (2.6%) | 77 |
| HBME1 + / Galectin3 + | 28 (57.1%) | 21 (42.9%) | 49 |
| HBME1 + / Galectin3 - | 13 (76.4%) | 4 (23.6%) | 17 |
| HBME1 - / Galectin3 + | 17 (81%) | (19%) | 21 |
Legend: ICC: Immunocytochemistry.
p-value <0.005